Finance

Stada nullifies its plan for an Initial Public Offering (IPO)

Stada's ambitious stock market debut earlier this week has been displaced by a fresh investor acquisition for the company.

, and Administrator

2025 September 12 . 3:40 AM

1 min read

Stada opts out of initial public offering (IPO)

Stada nullifies its plan for an Initial Public Offering (IPO)

In a significant development, Stada, the German pharmaceutical company headquartered in Bad Vilbel, has announced the sale of its majority stake to CapVest Partners, a London-based investment firm. The sale, subject to regulatory approvals and expected to close in the first half of 2026, marks one of the largest Initial Public Offerings (IPOs) this year.

The IPO valuation of Stada is estimated to be around ten billion euros. Despite the sale, the previous shareholders, Bain Capital and Cinven, will retain a minority stake in the company.

Stada is well-known for its popular cold remedy Grippostad and cough syrup Silomat. The announcement of the new investor, CapVest Partners, was made on Monday.

The decision to sell the majority stake comes after previous plans for an IPO were postponed due to significant market fluctuations in the spring. However, Stada CEO Peter Goldschmidt had indicated an IPO for the fall.

CapVest Partners, based in London, is joining Stada at a time when the company is undergoing one of the largest IPOs this year. The exact location of the company was not specified in the announcement, but it remains headquartered in Bad Vilbel.

This sale is not the first time Bain Capital and Cinven have sold their stake in a company. Both firms are based outside of Germany, reflecting their global investment portfolio.

The sale of the majority stake does not reveal the purchase price, but the IPO valuation of ten billion euros provides a significant insight into the value of Stada. The closing of the deal is eagerly anticipated by investors and stakeholders alike.